Navigation Links
Amikacin Inhale Shows Promising Results in Phase II Study
Date:5/19/2008

4) or every 12 hours (n=21) for 7-14 days.

Serial serum, tracheal aspirate and urine samples were collected on Day 3. Clinical parameters, such as Clinical Pulmonary Infection Score (CPIS), days on ventilator and intravenous antibiotic use were monitored. In another study healthy volunteers (n=14) inhaled a single dose of 400 mg of amikacin via the proprietary delivery system using the hand held adaptor. This was done to compare the lung doses between on-vent and hand-held adaptors using the same proprietary nebulizer.

Mean peak tracheal aspirate of amikacin after Amikacin Inhale use every 12 hours was 16,212 +/- 3,675 mcg/mL as compared to 14 +/- 4.2 mcg/mL after intravenous administration (15mg/kg per day)(3). After Amikacin Inhale use, peak serum levels of amikacin were 3.2 +/- 0.5 mcg/mL versus 47 +/- 4.2 mcg/mL after intravenous administration. On average, 43 percent of the dose was delivered to the lungs using the hand-held system with a comparable low systemic exposure. The dose delivered to the lungs with the proprietary nebulizer is comparable between the on-vent and hand-held adaptors.

Penetration of Amikacin Inhale in Lower Respiratory Tract(4)

This study evaluated Amikacin Inhale penetration into the fluid lining of the epithelial surface (ELF) of the lower respiratory tract of the pneumonia-infected lung. Treatment was adjunctive to IV treatment. Mechanically ventilated patients (n=28) with Gram-negative pneumonia received 400 mg doses of aerosolized amikacin every 12 hours for 7-14 days. The delivery of aerosolized Amikacin Inhale achieved high aminoglycoside amikacin concentrations in the ELF of the lower respiratory tract, including in the pneumonic area of the lung while maintaining safe serum concentrations. Median ELF levels were 976.1 mcg/mL [135.7-16,127.6], always exceeding the amikacin MIC (minimum inhibitory concentration) for microorganisms usually responsible for Gram-negative pneumonia.

High in vivo Amika
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
2. Inhaled Steriods Used as Preventive Treatment Post 9/11
3. Arriva Pharmaceuticals Moves Forward to Phase 2b Development of Lead Inhaled Protein rAAT Replacement Therapy for Hereditary Emphysema
4. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
5. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
6. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
7. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
8. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
9. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
10. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
11. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... 15 West Pharmaceutical Services, Inc. (NYSE: ... Directors has approved payment of the first-quarter 2010 cash ... paid on February 3, 2010 to shareholders of record ... ,, West is a global manufacturer of components ... seals for vials, and closures and disposable components used ...
(Date:12/15/2009)... 15 SRI International, an independent nonprofit ... of U.S. patent 7,592,021 for a new bioadhesive ... drugs through the human body,s mucous membranes. This ... allows for a much longer release time compared ... Transmucosal delivery is an effective means to introduce ...
(Date:12/15/2009)... SINGAPORE, Dec. 15 ... that it has completed the previously announced ... manufacturer of disposable medical devices ranging from ... surgery. Through its medical segment, Flextronics provides ... device, medical equipment, and pharmaceutical customers. Terms ...
Breaking Medicine Technology:SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System 2SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System 3SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System 4SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System 5Flextronics Completes SloMedical Acquisition 2Uni H A in France Signs Purchasing Agreement for Masimo SET 28R 29 Pulse Oximetry Products 14907 1Uni H A in France Signs Purchasing Agreement for Masimo SET 28R 29 Pulse Oximetry Products 14907 2Uni H A in France Signs Purchasing Agreement for Masimo SET 28R 29 Pulse Oximetry Products 14907 3Uni H A in France Signs Purchasing Agreement for Masimo SET 28R 29 Pulse Oximetry Products 14907 4Macomb County Health Department Schedules Communitywide H1N1 Flu Vaccine Clinic Nov 24 61652 1Macomb County Health Department Schedules Communitywide H1N1 Flu Vaccine Clinic Nov 24 61652 2National Patient Safety Foundation Supports Mandatory Flu Vaccinations for Healthcare Workers 61647 1National Patient Safety Foundation Supports Mandatory Flu Vaccinations for Healthcare Workers 61647 2National Patient Safety Foundation Supports Mandatory Flu Vaccinations for Healthcare Workers 61647 3
... is Designed to Differentiate Squamous From, Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Classifying ... of 90 ... Percent., Accurate Diagnosis is Important ... Potential Higher Rates of Severe or Fatal Hemorrhage in Patients With Squamous ...
... 2 DermaGen AB today announced a,cash injection from ... Development and Ostersjostiftelsen. The capital will be used for,the ... be used to initiate a clinical phase 2a study ... has already received approval, and,to further develop the company,s ...
Other Medicine Technology:Columbia University Medical Center and Rosetta Genomics Announce Columbia University's Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica 2Columbia University Medical Center and Rosetta Genomics Announce Columbia University's Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica 3Columbia University Medical Center and Rosetta Genomics Announce Columbia University's Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica 4Columbia University Medical Center and Rosetta Genomics Announce Columbia University's Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica 5Columbia University Medical Center and Rosetta Genomics Announce Columbia University's Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica 6Columbia University Medical Center and Rosetta Genomics Announce Columbia University's Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica 7DermaGen AB Receives Over 1 Million Euros From a New Share Issue 2DermaGen AB Receives Over 1 Million Euros From a New Share Issue 3
(Date:12/16/2009)... free nationwide confidential legal consultations for users of Paxil who ... Defects, Attempted Suicide, Suicide and Addiction Issues. Individuals suffering from ... go to the firm’s website at http://www.ennislaw.com and ... ... (PRWEB) December 16, 2009 -- Bloomberg news ...
(Date:12/16/2009)... Foods will be carrying Dr. Shapio,s Help Hair Shake in all of ... ... (PRWEB) December 16, 2009 -- Dr. Larry Shapiro, hair transplant ... Foods stores will be carrying the Help Hair Whey Protein Shake. ... suitable as an adjunct for weight loss programs, working out and muscle ...
(Date:12/15/2009)... successfully developed a new electrophoretic method for detecting ... The technique, using SARCOSYL-PAGE, has specifically enhanced ... performance characteristics of SDS-PAGE for detecting other EPOs. ... grant from the World Anti-Doping Agency (WADA), appear ... and Analysis published by Wiley-Blackwell. , MIRCERA ...
(Date:12/15/2009)... SUMMARY: The U.S. Senate today rejected an ... Act that would have helped make prescription drugs ... legal importation of lower priced drugs from abroad. ... by Senators Dorgan, Snowe, McCain, Grassley and Stabenow, ... down the skyrocketing costs of prescription drugs. ,, ...
(Date:12/15/2009)... Bulletin Board: SNKTY), a Life Sciences company engaged in the research, development and commercialization of ... three resolutions that the Company had proposed at the Annual General Meeting of Shareholders held ... of Votes ... Non-, Matter ... For Against ...
Breaking Medicine News(10 mins):Health News:Ennis & Ennis, P.A. Announces Nationwide Free Legal Consultations For Users of Paxil 2Health News:Ennis & Ennis, P.A. Announces Nationwide Free Legal Consultations For Users of Paxil 3Health News:Florida Whole Foods Stores to Carry Dr. Lawrence Shapiro's Help Hair Shake 2Health News:Researchers discover novel method for detecting MIRCERA 2Health News:AARP Disappointed By Senate Vote Against Lower Prescription Drug Prices 2Health News:AARP Disappointed By Senate Vote Against Lower Prescription Drug Prices 3Health News:Senetek PLC Announces 2009 Annual General Meeting Voting Results 2Health News:Senetek PLC Announces 2009 Annual General Meeting Voting Results 3
... the human growth hormone (HGH) industry approaches $2 ... athletic performance, anti-aging and stimulating growth. Unfortunately, many ... of independent review organizations (IROs) whose members see ... medical necessity of growth hormone therapies ( www.nairo.org ...
... Network,s CIO on Helping Organizations Protect Medical Records and Comply ... ... Scottsdale, Ariz. (PRWEB) April 14, 2009 -- With an increasing ... of new challenges to implement administrative, technical and physical security ...
... flow measurement and control provider, announced that it has acquired ... Key Instruments is a flow meter manufacturer based in Trevose, ... flow meters, glass tube flow meters, electronic flow meters, and ... applications. , ...
... 14 Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: ... of a New Drug Application (NDA) to the U.S. ... relapsed or refractory aggressive non-Hodgkin,s lymphoma (NHL). CTI expects ... priority review which if granted could lead to an ...
... allow BlackBerry® devices to securely connect to ActiveSync supported email ... or businesses that require ActiveSync for their mobility solution such ... Suite or the CommuniGate Pro Server. , ... ...
... and PLANO, Texas, April 13 Botox,s arch-nemesis, ... the U.S. cosmetics ring at any moment; whether ... slightly unfamiliar European cousin remains to be seen, ... a significant potential cost savings, is certainly provocative. ...
Other Medicine News:Health News:IROs Help Determine Medical Necessity of Growth Hormone Therapy 2Health News:Lumension Webinar Focuses on How to Protect Medical Records, Ensure HIPAA Compliance and Improve Productivity 2Health News:Lumension Webinar Focuses on How to Protect Medical Records, Ensure HIPAA Compliance and Improve Productivity 3Health News:Brooks Instrument Acquires Flow Products Supplier Key Instruments 2Health News:Cell Therapeutics Initiating Rolling NDA Submission for Pixantrone 2Health News:Cell Therapeutics Initiating Rolling NDA Submission for Pixantrone 3Health News:Cell Therapeutics Initiating Rolling NDA Submission for Pixantrone 4Health News:NotifySync™ Provides BlackBerry a Direct Connection to Any Email Platform Supporting Microsoft ActiveSync 2Health News:Botox(R) vs. Reloxin(R) -- the Wrinkle Titans Poised for Battle 2Health News:Botox(R) vs. Reloxin(R) -- the Wrinkle Titans Poised for Battle 3Health News:Botox(R) vs. Reloxin(R) -- the Wrinkle Titans Poised for Battle 4
MP-250N and 300N is a new style power supply. It is a versatile microprocessor power supply for horizontal or vertical gel electrophoresis. The unit is programmable and offers constant voltage and co...
Handy 100V Power Supply is Low-cost, compact and lightweight. Easy to operate - either 50 or 100 VDC is selectable as the output voltage. These voltages are sufficient for ordinary electrophoresis....
... ZOOM® Dual Power is a microprocessor-controlled ... both high voltage/low current and high ... voltage/low current section is ideal for ... DNA sequencing applications. The low voltage/high ...
... Power Supply is designed specifically ... extensive programming capabilities, including eight ... for you to set to ... intuitive PowerEase® interface is faster ...
Medicine Products: